The brain implants market is projected to grow from US$ 7.21 billion in 2022 to US$ 17.65 billion by 2030, at a CAGR of 11.8% ...

Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

Kootenai Health is focused on the future of Post Falls when considering the population projection numbers in the next 20 ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

Revenue: US$79.9m (up 22% from FY 2023). Net loss: US$27.1m (loss narrowed by 18% from FY 2023). US$0.93 loss per share ...

NeuroPace (NASDAQ:NPCE – Get Free Report) had its price objective boosted by equities research analysts at Cantor Fitzgerald from $19.00 to $20.00 in a report issued on Wednesday,Benzinga reports. The ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.

MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...